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In humans, Vg9Vd2 T cells detect tumor cells and mi-
crobial infections, includingMycobacterium tubercu-
losis, through recognition of small pyrophosphate
containing organic molecules known as phospho-
antigens (pAgs). Key to pAg-mediated activation
of Vg9Vd2 T cells is the butyrophilin 3A1 (BTN3A1)
protein that contains an intracellular B30.2 domain
critical to pAg reactivity. Here,wehavedemonstrated
through structural, biophysical, and functional ap-
proaches that the intracellular B30.2 domain of
BTN3A1 directly binds pAg through a positively
charged surface pocket. Charge reversal of pocket
residues abrogates binding and Vg9Vd2 T cell acti-
vation.Wehave also identified a gain-of-functionmu-
tation within this pocket that, when introduced into
the B30.2 domain of the nonstimulatory BTN3A3 iso-
form, transfers pAg binding ability and Vg9Vd2 T cell
activation. These studies demonstrate that internal
sensing of changes in pAgmetabolite concentrations
by BTN3A1 molecules is a critical step in Vg9Vd2
T cell detection of infection and tumorigenesis.
INTRODUCTION
In humans, 2%–5% of T cells in the blood belong to a unique
population of gd T cells that express a T cell receptor (TCR)
composed of Vg9 and Vd2 chains (Bonneville and Scotet,
2006; Morita et al., 2007). Known as Vg9Vd2 T cells (or Vg2Vd2
by a different nomenclature system), these cells can expand to
approximately 20% of circulating T cells in individuals during in-
fections by a range of microbial pathogens such as Plasmodium
falciparum andMycobacterium tuberculosis (Chen, 2013) and in
some individuals can reach upward of 90% of circulating T cells
(Morita et al., 2007). Expansion of Vg9Vd2 T cells has also been
observed in patients with lymphoid malignancies (McClanahan490 Immunity 40, 490–500, April 17, 2014 ª2014 Elsevier Inc.et al., 1999). In vitro, Vg9Vd2 T cells target certain cancer cell
lines or cells treated with microbial extracts (Tanaka et al., 1994).
Vg9Vd2 T cell reactivity has been traced to accumulation of
organic pyrophosphate molecules commonly known as phos-
phoantigens (pAgs) (Constant et al., 1994; Hintz et al., 2001;
Puan et al., 2007; Tanaka et al., 1995). These molecules are pro-
duced either endogenously, such as isopentenyl pyrophosphate
(IPP), an intermediate of the mevalonate pathway in human cells
that can accumulate intracellularly during tumorigenesis, or
by microbes, such as hydroxy-methyl-butyl-pyrophosphate
(HDMAPP, also known as HMBPP), a microbial intermediate of
the 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway. Along
this line, treatment with pharmacological inhibitors of the meval-
onate pathway (e.g., aminobisphosphonates [NBP]), which lead
to intracellular accumulation of IPP, sensitizes cells to Vg9Vd2
T cell recognition (Gober et al., 2003; Kunzmann et al., 1999,
2000). Synthetic pAgs such as ethyl pyrophosphate (EtPP)
or bromohydrin pyrophosphate (BrHPP) also show potent stim-
ulatory ability when added exogenously (Boe¨dec et al., 2008;
Eberl et al., 2003; Espinosa et al., 2001; Zhang et al., 2006).
The relative potency of these pAgs varies more than 1,000-fold
between the more potent exogenous HDMAPP and the endoge-
nous ligand IPP.
The Vg9Vd2 TCR is necessary and sufficient for pAg recogni-
tion (Bukowski et al., 1995) yet cell-to-cell contact between the
T cell and pAg-treated cell is required for stimulation, suggesting
the presence of a target-cell-associated ligand (Lang et al., 1995;
Morita et al., 1995). Cells of a nonprimate origin treated with pAg
do not stimulate Vg9Vd2 T cells (Wang et al., 2003; Wei et al.,
2008), which suggests that a primate-specific protein or proteins
is required on the target cell for pAg-induced activation of
Vg9Vd2 T cells. Previous work by our groups and others has
established the required role for the butyrophilin-3A (BTN3A,
also known as CD277) subfamily of proteins in mediating pAg
signaling (Harly et al., 2012; Palakodeti et al., 2012; Vavassori
et al., 2013; Wang et al., 2013). The BTN3A subfamily contains
three members in humans: BTN3A1, BTN3A2, and BTN3A3
(Rhodes et al., 2001). Each subfamily member contains an extra-
cellular, N-terminal IgV and a membrane-proximal IgC domain
connected to a single-pass transmembrane domain. BTN3A1
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Figure 1. Phosphoantigen Reactivity Is Mapped to the BTN3A1
Intracellular B30.2 Domain
(A) Percentage of human Vg9Vd2 T cells expressing CD107a after coculture
with HEK sh284 cells mock-transfected (Mock) or re-expressing, after tran-
sient transfection, either wild-type (WT) BTN3A1 or BTN3A3 isoforms or
chimeric BTN3A3 proteins assembled with the BTN3A1 B30.2 domain with
(BTN3A3 B30.2 A1) or without (BTN3A3 B30.2 A1 short) the extra C-terminal
tail of BTN3A3. Target cells were pretreated for 2 hr with the a-CD277 mAb
20.1 (10 mg/ml) or the NBP zoledronate (100 mM). Data are representative of
three independent experiments.
(B) Amino acid sequence alignment of the B30.2 domains of BTN3A1 (top) and
BTN3A3 (bottom). Positions identical to BTN3A1 are shown as dashes and
differences are shown in capital letters. Dots indicate the region missing in
BTN3A1. The swapped regions are indicated and labeled accordingly (Box 1,
Box 2, and Box 3, abbreviated as b1, b2, and b3, respectively). Numbering
corresponds to the full-length sequence of BTN3A proteins.
(C) Percentage of human Vg9Vd2 T cells expressing CD107a after coculture
with NBP-treated mutant-BTN3A HEK293 transfectants. Full-length BTN3A3,
which does not mediate pAg activation of Vg9Vd2 T cells, had the corre-
sponding BTN3A1 regions (b1, b2, b3, or a combination thereof) swapped into
the intracellular B30.2 region. These mutants were used as targets for treat-
ment with NBP (NBP) or vehicle (-) and the Vg9Vd2 response wasmeasured as
CD107a upregulation. Data are presented as mean of specific values ± SD of
the percentage of CD107a-positive gd T cells (nR 3).
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BTN3A1 B30.2 Domain Mediates Vg9Vd2 pAg ActivationandBTN3A3 both contain an intracellular B30.2 domain, which is
missing in BTN3A2. All three isoforms, when treated with the
20.1 agonist antibody, confer a stimulatory signal to Vg9Vd2
T cells, suggesting the involvement of their extracellular domains
in the activation process. However, only the BTN3A1 isoform
mediates pAg-induced activation, a feature we and others
have shown to require the presence of its intracellular domain
containing a B30.2 domain (Harly et al., 2012; Wang et al.,
2013). The intracellular domain of the BTN3A3 isoform also
contains a B30.2 domain, but BTN3A3 cannot stimulate in a
pAg-dependent manner (Harly et al., 2012).
Here we have presented our molecular and functional charac-
terization of the intracellular BTN3A1 B30.2 domain and demon-
strated that it senses elevated concentrations of pAgs through a
positively charged surface pocket. Mutagenesis of this pocket
abrogated pAg binding and the ability of BTN3A1 to mediate
Vg9Vd2 T cell stimulation. Furthermore, we identified a single
amino acid difference in the B30.2 domain of the nonstimulatory
BTN3A3 that, when mutated to the corresponding residue in
BTN3A1, conferred the ability to bind pAg and to activate
Vg9Vd2 T cells. Our data support the B30.2 intracellular domain
as the sensor for detecting changes in pAg metabolite concen-
trations. We propose that intracellular B30.2 pAg binding initi-
ates a cascade of events that induces extracellular changes or
rearrangements (including immobilization of BTN3A extracellular
domains) on the cell surface, leading to Vg9Vd2 T cell stimula-
tion. These results suggest a mechanism through which intracel-
lular recognition, and not extracellular presentation, of pAgs is
essential to mediating T cell stimulation.
RESULTS
Phosphoantigen-Mediated Stimulatory Activity of
BTN3A1 Maps to the N-Terminal Region of the B30.2
Domain
Previous results from our groups and others have demonstrated
that the intracellular portion of BTN3A1, which contains a B30.2
domain, is necessary to mediate pAg stimulation of Vg9Vd2
T cells (Harly et al., 2012; Wang et al., 2013). The closely related
BTN3A3 isoform, also containing a B30.2 domain in its intracel-
lular domain followed by a 70 amino acid C-terminal tail, is
incapable of stimulating Vg9Vd2 T cells in the presence of pAg.
To determine whether pAg-related activity was contained within
the B30.2 domain, we swapped the B30.2 domain of BTN3A3 for
that of BTN3A1 and tested whether this hybrid construct could
activate in a pAg-dependent manner. Nonreactive BTN3A
shRNA-silenced cells transfected with this hybrid construct
potently stimulated Vg9Vd2 T cells after treatment with the
bisphosphonate zoledronate (NBP) (Figure 1A). Removal of the
70 amino acid C-terminal cytoplasmic tail of BTN3A3 from this
hybrid did not substantially affect the stimulatory ability, sug-
gesting that pAg-mediated activation is restricted to the
core B30.2 sequence. To further dissect which regions of the
B30.2 domain of BTN3A1 are involved in pAg activity, we
swapped three regions of sequence of BTN3A1, indicated as
Boxes 1, 2, and 3 in Figure 1B, either individually or in combina-
tion into BTN3A3. The resulting full-length hybrid constructs
were tested for their ability to mediate pAg-induced Vg9Vd2
T cell stimulation. In each case, the sequence in Box 1 producedImmunity 40, 490–500, April 17, 2014 ª2014 Elsevier Inc. 491
Figure 2. Crystal Structure of the BTN3A1 Intracellular B30.2 Domain at 1.4 A˚ Resolution
(A) Ribbon diagram of the BTN3A1 B30.2 domain dimer observed in the crystal lattice. Monomers of B30.2 are shown in orange and blue with the N and C termini
of each shown as blue and red spheres, respectively. The two b sheets that compose the core of the B30.2 domain, sheet A and sheet B, are indicated. The
putative position of the N-terminal linker regions in relation to the transmembrane domain are shown as dashed lines and the plasma membrane is modeled in
pink. A monomer is oriented below the dimer to indicate the orientation shown as electrostatic surface, to the right. The electrostatic potential is shown rendered
on the B30.2 domain surface. The surface is colored from red (20 kT) to blue (20 kT) with the basic pocket indicated by a dashed yellow box.
(B) Close-up of the putative pAg binding pocket showing the six basic residues contributing to the highly positive charge of the pocket. These residues are shown
as sticks under a transparent surface colored according to the electrostatic potential.
(C) Rotated view of (B) showing the results ofmolecular docking performed by Autodock Vina. A best-fit docking position of the pAg, HDMAPP, is shown by a stick
model; it is well positioned in the binding pocket with a free energy (DG) calculated to be 5.6 kcal/mol, with the b-phosphate coordinated by the three arginines
R12, R418, and R469.
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BTN3A1 B30.2 Domain Mediates Vg9Vd2 pAg Activationa gain-of-function phenotype for BTN3A3 in NBP-treated cells,
either alone or in combination with other sequence ranges (Fig-
ure 1C). Therefore, we concluded that the difference in response
to pAgmapped to one or more of the eight sequence differences
between the B30.2 domains of BTN3A1 and BTN3A3 located in
the Box 1 region.
The 1.4 A˚ Structure of BTN3A1 B30.2 Domain Reveals a
Basic Pocket Suitable for Phosphoantigen Binding
To better understand the role the B30.2 domain plays in
pAg-mediated activation, we determined the structure of the
BTN3A1 B30.2 domain to 1.4 A˚ resolution (Figure 2A). The
domain crystallized with one molecule in the asymmetric unit
and the structure was refined to an Rcryst/Rfree of 13.5%/16.6%
(Table S1 available online). The BTN3A1 B30.2 domain adopted
a general B30.2 architecture (Woo et al., 2006): a b sandwich
formed by two sets of antiparallel b sheets (sheets A and B)
that form the SPRY domain and are extended by the N-terminal
PRY b strands. This B30.2 domain had high structural similarity
to the B30.2 domain contained within the intracellular IgG recep-
tor, Trim21 (Keeble et al., 2008), with a root-mean-square devia-
tion (rmsd) of only 0.75 A˚ between theCabackbone structures. In
our structure, one crystal contact formed a symmetrical dimer-
ization interface around the N-terminal a helix that connects to
the transmembrane domain in the full-length protein (Figure 2A).492 Immunity 40, 490–500, April 17, 2014 ª2014 Elsevier Inc.This dimer interface buried approximately 560 A˚2 (PDBePISA
server: http://www.ebi.ac.uk/msd-srv/prot_int/cgi-bin/piserver),
suggesting a possible physiologically relevant dimer consistent
with the dimer architecture identified in our structures of the
BTN3A extracellular domains verified via fluorescence reso-
nance energy transfer (FRET) analysis (Palakodeti et al., 2012).
Some but not all B30.2 domain crystal structures show dimer in-
terfaces similar to that observed in our structure (PDB ID: 2WL1
and4B8E). Examination of theB30.2 oligomeric state viamultian-
gle light scattering (MALS), however, showed that the B30.2
domain was predominately monomeric in solution at moderate
to high (2–10 mg/ml) protein concentrations (Figure S1).
Because all known pAgs contain a negatively charged pyro-
phosphate group, we next calculated the electrostatic surface
of the B30.2 domain to identify any obvious positively charged
pockets that might indicate potential pAg binding sites. A highly
positively charged surface formed by the close proximity of three
arginines (R412, R418, and R469), two histidines (H351 and
H378), and a single lysine (K393) was immediately identified on
the surface of sheet A (Figure 2B). Density for these side chains
was well resolved at 1s, although multiple rotomers were
observed for K393, R412, and H351. Of note, H351 is one of
the candidate positions identified in our sequence swapping
analysis shown in Figure 1, further implicating this region of the
B30.2 domain in pAg binding.
AB
Figure 3. Binding of Phosphoantigen to the BTN3A1 Intracellular B30.2 Domain
(A) Raw ITC traces showing injection of pAg into solution containing either the BTN3A1 B30.2 domain (black) or buffer (gray). Binding measurements were
performed with 100 mMB30.2 in the cell and 2.0 mM pAg in the syringe. The binding isotherms showing binding of the different pAgs to the BTN3A1 intracellular
B30.2 domain are shown to the right, plotted on the same axis for comparison. Buffer control is shown as open circles, IPP as open triangles, EtPP as filled
triangles, HDMAPP as open squares, and cHDMAPP as filled squares. The chemical structure of each pAg is shown under the binding isotherm traces.
(B) Binding measurements of the highly potent cHDMAPP to the extracellular domain of BTN3A1 (black) or buffer control (gray). Measurements were performed
with 100 mM BTN3A1 extracellular domain in the cell and 2 mM cHDMAPP in the syringe. The binding isotherms are shown with buffer control (open circle) or
cHDMAPP (filled square) to the right.
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BTN3A1 B30.2 Domain Mediates Vg9Vd2 pAg ActivationWe then used Autodock Vina, a computational modeling pro-
gram using Monte Carlo calculations, to identify potential pAg
binding sites. Using a 10,000 A˚3 search box with the identified
basic pocket at the center, multiple searches were performed to
find the best-fit docking of the pAg. These calculations repeat-
edly docked the pAg in the positively charged pocket (Figure 2C)
with an estimated binding energy (DG) of5.6 kcal/mol. The two
negatively charged phosphates were positioned such that they
were coordinated by the three arginines whereas the organic
chain of the pAg was located at the edge of the pocket, in a
more neutral region.
The BTN3A1 B30.2 Domain Directly Binds
Phosphoantigen
Our structural and sequence swapping studies strongly impli-
cated the B30.2 domain of BTN3A1 as the binding partner of
pAg. To directly test this, we used isothermal titration calorimetry
(ITC) to measure the interaction of pAgs with the B30.2 domain.
We tested four pAgs of varying stimulatory potency: IPP,
EtPP, HDMAPP, and hydroxy-methyl-butyl-pyrophosphonate
(cHDMAPP), a synthetic paralog to HDMAPP containing a phos-
phonate linkage in place of the phosphate linkage of HDMAPP.cHDMAPP is reported to have similar potency but greater stabil-
ity than HDMAPP (Boe¨dec et al., 2008). Clear binding to B30.2
was observed with each of the pAgs (Figure 3A). Fitting of the
ITC data revealed that the high-potency agonists HDMAPP
and cHDMAPP bound with a similar affinity of approximately
0.5 mM, whereas IPP and EtPP bound with 0.5 mM, correlating
with their 1,000-fold difference in potency as Vg9Vd2 T cell ago-
nists (Figure S2A and Table S2). Vavassori et al. (2013) have pro-
posed that pAg associates with the extracellular domain of
BTN3A1. However, we were unable to detect binding of the
highest-potency pAg (cHDMAPP) to the complete extracellular
domain of BTN3A1 via ITC at different temperatures (Figures
3B and S2B). These results demonstrate that the B30.2 intracel-
lular domain of BTN3A1 is the direct receptor for pAg binding.
To determine whether the positively charged pocket identified
in our structural studies was the site of pAg binding, we made
charge-reversal mutations to five of the basic residues in the
pocket: H378D, K393D, R412E, R418E, and R469E. This mutant
expressed and purified similarly to the wild-type B30.2 domain
(data not shown). When ITC was used to measure binding of
the high-potency pAg cHDMAPP for this mutant, no detectable
binding was observed (Figure 4A). Therefore, changing theImmunity 40, 490–500, April 17, 2014 ª2014 Elsevier Inc. 493
A B Figure 4. Charge Reversal of Putative pAg
Binding Pocket Residues Prevents pAg
Binding and Vg9Vd2 Activation
The residues of the B30.2 basic pocket were
mutated as follows: H378D, K393D, R412E, R418E,
and R469E.
(A) Shown are the binding isotherms of cHDMAPP
with the B30.2 domain (filled squares), the B30.2
charge-reversal mutant (filled triangle), and a buffer
control (open circles).
(B) Vg9Vd2 T cell stimulation as assessed by
CD107a upregulation is shown in response to no
stimulation (No stim.), addition of the a-CD277
agonist antibody 20.1, or in the presence of the
bisphosphonate zoledronate (NBP). Data are pre-
sented as mean of specific values ± SD of the
percentage of CD107a-positive gd T cells (n R 3).
*p < 0.05 (Student’s t test).
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BTN3A1 B30.2 Domain Mediates Vg9Vd2 pAg Activationcharge of the basic pocket from positive to negative ablates pAg
binding, supporting this as the site of pAg binding. We also
tested the effect the charge reversal had on the ability of
BTN3A1 to stimulate Vg9Vd2 T cells in a pAg-dependent fashion.
Consistent with the inability to bind pAg, charge reversal of this
pocket in the B30.2 domain of the full-length BTN3A1 protein
failed to support pAg-dependent stimulation of Vg9Vd2 T cells
(Figure 4B).
Phosphoantigen Reactivity Is Transferred to BTN3A3
through a Single Amino Acid Change in the Binding
Pocket
Although only BTN3A1 is able to mediate pAg stimulation of
Vg9Vd2 T cells, the closely related BTN3A3 isoform also contains
a B30.2 domain that shares 87% sequence identity with that of
BTN3A1. Our sequence swapping results shown in Figure 1 indi-
cated that sequence differences in Box 1 were linked to pAg
reactivity and that one of these residues, position 351, was
located within the pAg binding pocket; BTN3A1 has a histidine
and BTN3A3 an arginine at this position (Figure 1B). To charac-
terize the role of position 351 on pAg binding, we constructed
sequence-swapped BTN3A1 and BTN3A3 mutants and tested
them via ITC. As a control, we included constructs with a
sequence swap mutation distal to the pAg binding site (position
426) or with the C-terminal tail of BTN3A3 removed. Neither
the distal mutation K426E nor removal of the C-terminal tail
(amino acids 485–555) affected pAg binding via ITC (Fig-
ure 5A), but the binding pocket mutants BTN3A1_H351R and
BTN3A3_R351H demonstrated a dramatic reversal of binding:
loss of pAg binding for BTN3A1_H351R and gain of pAg binding
for BTN3A3_R351H.
We next determined whether this single amino acid difference
was responsible for the observed differences in Vg9Vd2 T-cell-
stimulatory capability between BTN3A1 and BTN3A3. As
described previously (Harly et al., 2012), we used shRNA to
silence endogenous BTN3A and then reintroduced into cells
the individual BTN3A isoforms and the corresponding position
351 mutants. We measured the ability of the cells to stimulate
Vg9Vd2 T cells either after treatment with the agonist 20.1 anti-
body or after NBP treatment (Figure 5B). Consistent with what
we observed for pAg binding, BTN3A1_H351R was unable to
mediate NBP-induced stimulation of Vg9Vd2 T cells, even494 Immunity 40, 490–500, April 17, 2014 ª2014 Elsevier Inc.though it was able to stimulate after treatment with the
agonist antibody 20.1. Unlike the WT BTN3A3 protein, the
BTN3A3_R351Hmutant was able tomediate NBP-induced stim-
ulation of Vg9Vd2 T cells and did so even more potently than did
theWT BTN3A1 protein. Similar results were obtained with treat-
ment of these mutants with the soluble pAg BrHPP (Figure S3),
supporting that the NBP-induced effect is due to an elevation
in pAg concentration.
Previously we demonstrated that addition of the agonist 20.1
antibody or NBP to target cells resulted in immobilization of
BTN3A1 on the cell surface (Harly et al., 2012), suggesting that
BTN3A1 immobilization is an important step in the induction of
Vg9Vd2 T cell stimulation. To determine whether pAg binding
to the B30.2 domain was required for this immobilization to
occur, we repeated this experiment with our BTN3A1_H351R
mutant. Wild-type and mutant BTN3A were engineered with a
C-terminal mCherry tag for visualization and reintroduced into
BTN3A-silenced cells. These constructs behaved similarly to
untagged BTN3A constructs in their ability to stimulate Vg9Vd2
T cells after 20.1 or NBP addition (Figure 5C), indicating that
addition of the C-terminal tag was not disruptive. Fluorescence
recovery after photobleaching (FRAP) measurements of these
transfected cells after incubation with NBP revealed clear immo-
bilization of BTN3A1 containing a wild-type, pAg-binding-profi-
cient, B30.2 domain. In marked contrast, cells transfected with
a BTN3A1 construct containing the non-pAg binding, B30.2
domain mutant H351R showed no FRAP difference compared
to untreated cells (Figure 5D). These results again support our
model in which binding of pAg by the B30.2 domain of the
BTN3A proteins induces cell-surface immobilization of BTN3A1
molecules, leading to stimulation of Vg9Vd2 T cells.
Complex Crystal Structure Locates Phosphoantigen in
the Positively Charged Pocket of the B30.2 Domain
To further characterize the mode of pAg binding to the BTN3A1
B30.2 domain, we next pursued structural studies of cHDMAPP
in complex with B30.2. Initial attempts to soak cHDMAPP into
existing B30.2 crystals failed because addition of cHDMAPP to
pregrown crystals caused the crystals to dissolve. Attempts at
cocrystallizing pAg with the B30.2 domain generated no crystals
of diffraction quality. We therefore used glutaraldehyde cross-
linking to stabilize our apo crystals followed by soaking with
Figure 5. A Single Amino Acid Difference Mediates pAg Reactivity between the BTN3A1 and BTN3A3 B30.2 Domains
(A) ITC binding isotherms comparing the binding of cHDMAPP to the wild-type BTN3A1 (pAg-responsive) B30.2 domain or mutants containing the respective
BTN3A3 (pAg-inactive) residue are shown at left. Binding of cHDMAPP is shown to B30.2 (filled squares), H351R (filled diamonds), K426E (open triangle), or the
buffer control (open circle). At right are the ITC binding isotherms comparing the binding of cHDMAPP to the wild-type BTN3A3 B30.2 domain ormutants in which
the relevant BTN3A1 residues are introduced. A BTN3A3 B30.2 domain mutant lacking the additional 70 C-terminal residues (D485–555) was also assessed for
pAg binding. Binding of cHDMAPP is shown to B30.2 (filled squares), R351H (filled diamonds), the C-terminal truncation D485–555 (filled triangles), E427K (open
triangle), or the buffer control (open circle).
(B) FACS plots showing CD107a upregulation of Vg9Vd2 T cells in response to treatment of wild-type and sequence-swapped B30.2 domain full-length BTN3A
constructs with a-CD277 agonist antibody 20.1 or in the presence of the bisphosphonate zoledronate (NBP).
(C) Functionality of fluorescent wild-type and mutated BTN3A1 chimeras are shown via FACS plots showing CD107a upregulation on Vg9Vd2 T cells (polyclonal
line) after coculture with CD277shRNA#284 transduced-HEK293FT cells transiently transfected for the expression of either wild-type (WT) or H351R B30.2
domain mCherry full-length BTN3A1 constructs. Cells were treated with a-CD277 agonist antibody (clone #20.1) or the aminobisphosphonate zoledronate (NBP)
before coculture. Numbers adjacent to outlined areas indicate the percentage of CD107a+ T cells.
(D) Top: Representative confocal images of HEK293 cells expressing mCherry-WT or -H351R BTN3A1 molecules after overnight incubation with NBP, shown
before (Pre-bleach), immediately after (T0-bleach), and 120 s after (T120) photobleaching of regions of interest (indicated rectangular areas). Scale bars represent
3 mm.Bottom: FRAP analysis of HEK293 cells expressing either wild-type or H351RB30.2 domainmCherry full-length BTN3A1molecules, without treatment (-) or
after incubation with NBP or a-CD277 agonist mAb (20.1). Data are presented as the value for the percentage of immobile fraction. FRAP was collected every 5 s.
Control: no treatment, (-). BTN3A1 WT: (-), n = 48; NBP, n = 34; a-CD277, n = 20. BTN3A1 H351R: (-), n = 19; NBP, n = 15; a-CD277, n = 19. Bars indicate mean
values. Student’s t test: ***p < 0.005.
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BTN3A1 B30.2 Domain Mediates Vg9Vd2 pAg ActivationcHDMAPP. These crosslinked and soaked crystals diffracted
well and the data set was refined to an Rcryst/Rfree of 15.3%/
19.0% (Table S1) and showed clear tetrahedral electron density
consistent with the b- and a-phosphates of the pAg, placing it
directly in the binding pocket in a conformation similar to what
was proposed by our docking results (Figure 6). The b-phos-
phate establishes seven hydrogen bonds with the three argi-nines it contacts: R412, R418, and R469 (Figure 6A). Two
additional water-mediated hydrogen bonds are established
with both phosphates with the main-chain nitrogen of M394.
The organic chain is poorly resolved in the electron density, sug-
gesting that it is highly mobile in the crystal structure.
It must be noted that identification of small molecules via crys-
tallography is exceptionally difficult because there is no de novoImmunity 40, 490–500, April 17, 2014 ª2014 Elsevier Inc. 495
A B
C
Figure 6. Structure of cHDMAPP in Complex with B30.2 Domain of
BTN3A1
(A) B30.2 is shown in ribbon format in orange, with pAg binding pocket resi-
dues shown as sticks. cHDMAPP is shown as sticks with spheres, and specific
atoms are shown with standard coloring (carbon, yellow; red, oxygen; blue,
nitrogen; and orange, phosphate). Hydrogen bonds % 3.3A˚ are shown as
yellow dashes. Water molecules are shown as blue spheres.
(B) Omit map density of cHDMAPP is shown in teal scaled at 1s.
(C) Positive density observed in the complex structure but missing in the apo
structure as identified from the isomorphous difference map is shown in green
scaled at 4s.
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from the modeled molecule. Omit map density of our pAg in
the binding pocket was unambiguous (Figure 6B), but because
our apo- and pAg-soaked crystals were isomorphous, we veri-
fied our pAg density through an isomorphous differencemap be-
tween our apo B30.2 and cHDMAPP and B30.2 complex data
sets. We clearly observed, even at 4s, tetrahedral density that
corresponds to the position of the b-phosphate phosphorus (Fig-
ure 6C). This density is inconsistent with the structure of glutar-
aldehyde, the only additional additive in the complex crystals,
verifying that the observed density must belong to cHDMAPP.
This high-resolution complex structure also allows closer ex-
amination of the effect that a histidine-to-arginine change at
position 351 would have upon pAg binding. Our complex struc-
ture showed both electrostatic and hydrogen-bonding contacts
making important contributions to pAg binding. Position 351, a
histidine in the BTN3A1 B30.2 domain that is competent to
bind pAg, was essentially buried, contributing only a small per-
centage to the exposed surface that comprises the pAg binding
pocket and not establishing any direct contacts with the pAg.
Introduction of an arginine side chain at this position would
require considerable rearrangement of the surrounding residues,
probably resulting, at a minimum, in a structural change to the
binding pocket and more likely causing broader structural
changes to the B30.2 domain. Anecdotally, we have observed
lower protein stability and solubility at high concentrations with
recombinantly produced BTN3A3 B30.2 domain (R351) as well
as the BTN3A1 B30.2 domain containing the H351R mutant,
suggesting that this side chain difference has consequences to
protein structure beyond the pAg binding pocket.
The apparent contradiction of our biophysical, structural, and
functional results establishing the B30.2 domain as the pAg
sensor with those previously published by Vavassori et al.496 Immunity 40, 490–500, April 17, 2014 ª2014 Elsevier Inc.(2013) led us to re-examine the electron density presented in
their complex structure. We downloaded the structure factors
and coordinate files (PDB IDs: 4JKW and 4K55) from the
RCSB and calculated omit maps (whereby the ligand is omitted
from the model during map calculation to generate unbiased
electron density). In the electron density calculated by these
means, a clear circular density was apparent surrounding the
central lysine (K39) in both their BTN3A1V structures (Figure S4).
This density is inconsistent with the structure of a pAg, where the
phosphate moieties would have much stronger scattering ability
(and thus greater electron density) than the organic portion.
Instead, a polyethylene glycol (PEG) molecule, a major compo-
nent of the crystallization solution used to obtain the BTN3A1V
crystals, modeled into this site fits this electron density well.
PEGs can interact with lysines similar to crown ethers (Julian
and Beauchamp, 2001; Kotlyar et al., 2005) whereby the proton-
ated amino group of the lysine hydrogen bonds with the oxygen
atoms of the PEG.We therefore believe that the electron-density
maps of this region have been inadvertently misinterpreted. This
proposed binding site was also inconsistent with previously pub-
lished data demonstrating that BTN3A2 does not mediate pAg-
induced activation of Vg9Vd2 T cells, because the pAg binding
site proposed in their crystal structure is completely conserved
between BTN3A1 and BTN3A2.
No Association Detected between the BTN3A1
Extracellular Domain and the Vg9Vd2 TCR
To determine whether the Vg9Vd2 TCR was binding directly to
the BTN3A1 extracellular domain, we performed surface plas-
mon resonance (SPR) with BTN3A1 alone and in combination
with the agonist antibody (20.1) single chain, which forms a com-
plex competent to induce Vg9Vd2 T cell activation (Harly et al.,
2012; Palakodeti et al., 2012). Despite our use of the high immo-
bilization density of the Vg9Vd2 G115 TCR (Davodeau et al.,
1993) and high concentrations of 20.1-complexed BTN3A1 ana-
lyte, no binding was detected (Figure 7A). At these protein con-
centrations, detectable binding should be observed at affinities
of 500 mM or stronger, suggesting that if these proteins do
interact, it is with an exceedingly weak affinity. Furthermore,
binding was not detected via SPRwith a reversed immobilization
strategy and AmDex multimerized G115 Vg9Vd2 TCR (60mers)
as analyte and full-length BTN3A1 extracellular domains site
specifically immobilized on the SPR chip surface (Figure 7B), a
strategy similar to that used by Vavassori et al. (2013). We
observed high, nonspecific background binding of the AmDex-
conjugated TCRs to the sensor-chip surface (Figure 7B); there-
fore, all G115 and TCR negative-control measurements were
subtracted from a surface immobilized with the murine nonclas-
sical class I molecule T22. The G8 TCR, specific to T22, was
used as a positive control for our AmDex multimerization; we
see a substantially slower dissociation rate with the AmDex-
multimerized G8 TCR when flowed over a T22-immobilized
surface (Figure 7B), reference subtracted from a BTN3A1 immo-
bilized flowcell. Finally, transfection of full-length BTN3A1 into
the murine neuroblastoma cell line NXS2 failed to support
Vg9Vd2 T cell stimulation either in the presence of pAg or through
the addition of the 20.1 agonist antibody, supporting the hypoth-
esis that BTN3A1 was necessary but not sufficient for Vg9Vd2
T cell activation and that another, primate-specific molecule or
AB
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Figure 7. BTN3A1 Is Necessary but Not Sufficient to Stimulate Vg9Vd2 T Cells
(A) SPR analysis of injections of the BTN3A1 extracellular domain, 20.1 single chain antibody, and the BTN3A1 extracellular domain in complex with the 20.1
single chain antibody from 0.03125 mM to 4 mM (black) flown over immobilized G115 Vg9Vd2 TCR. Control injections of buffer alone for each experiment are
shown in gray.
(B) Multimerized G115 gd TCRs do not bind recombinant, full-length BTN3A1. AmDex multimerized TCRs were made by conjugating C-terminally biotinylated
TCRs at a 60:1 ratio with streptavidin-conjugated AmDex polymers. Serial dilutions from 1 mg/ml to 0.03125 mg/ml of AmDex TCRswere injected over immobilized
full-length BTN3A1 and the murine T22 protein. Because nonspecific interactions were observed between the TCR conjugates and the biotin-coated reference
flow cell (AmDex-G115 reference cell), specific binding was measured by subtracting nonspecific interactions with T22 from the signal from BTN3A1 channel.
This analysis was reversed for the G8 murine TCR. Coinjection of 1 mM cHDMAPP with the G115 AmDex conjugate did not alter observed interactions.
(C) Rodent cells expressing full-length humanBTN3A1 do not activate human Vg9Vd2 T cells after agonist 20.1 a-CD277mAb or NBPpretreatment. Expression of
CD107a on Vg9Vd2 T cells after coculture with NXS2 murine neuroblastoma tumor cells expressing full-length human BTN3A1 or BTN3A2 after transient
transfection. 36 hr after transfection, surface expression of BTN3A was confirmed by flow cytometry. Target cells were pretreated for 2 hr with agonist 20.1
a-CD277 mAb (10 mg/ml) or the NBP Zoledronate (100 mM). Data are presented as the mean of specific values ± SD of the percentage of CD107a-positive gd
T cells. Positive control: human HEK293 cells. Similar results were obtained with the following rodent cell lines also transfected for the expression of human
ICAM-1: AB1, mouse; MC38, mouse; M5T1, rat.
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TCR (Figure 7B).
DISCUSSION
The molecular mechanisms by which Vg9Vd2 T cells respond
to changes in endogenous (tumor-derived) or exogenous
(microbial-derived) pyrophosphate-based metabolites have
been challenging to define. Our previous work showing that all
three human BTN3A molecules can mediate pAg-independent
Vg9Vd2 T cell stimulation in the presence of the 20.1 agonist anti-
body demonstrated the importance of the BTN3A extracellular
domain in this process (Harly et al., 2012). Addition of this anti-
body induced a marked immobilization of BTN3A on the cellsurface, providing insight into the molecular steps that occur
on the extracellular surface of target cells in order to engage
Vg9Vd2 T cells. The role of pAg, however, remained unclear.
Although previous work by others (Vavassori et al., 2013;
Wang et al., 2010) postulated that pAg is presented to Vg9Vd2
T cells in a manner homologous to antigen presentation by
MHCmolecules, our data instead support an unexpected mech-
anism for intracellular pAg detection.
Our structural, biophysical, and mutagenic approaches
showed that pAgs bind with functionally relevant affinities to a
positively charged pocket formed by sheet A of the B30.2
domain (Woo et al., 2006). This pocket, lined by the basic resi-
dues H351, H378, K393, R412, R418, and R469, is a specialized
feature of the BTN3A B30.2 domains. These residues are strictlyImmunity 40, 490–500, April 17, 2014 ª2014 Elsevier Inc. 497
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species that maintain the Vg9Vd2 T cell population (Wang
et al., 2003) but are not conserved in B30.2 domains found in
other proteins. The finding that one pocket residue difference
between the B30.2 domains of BTN3A1 and BTN3A3 deter-
mines pAg binding (H351R) suggests yet another level of special-
ization of the BTN3A1 isoform for this activity. It is unclear what
function, if any, the BTN3A2 or BTN3A3 isoforms perform in this
system.
Although pAg binding to the extracellular surface of target cells
for activation of Vg9Vd2 T cells is a simple and attractive model
(Vavassori et al., 2013), our data do not support this mechanism
of action. We observed no binding of pAgs to the extracellular
domain of BTN3A1 despite using high concentrations of protein
and pAg in our ITC experiments. We have also been unable
to detect interactions between the extracellular domain of
BTN3A1 with that of the Vg9Vd2 TCR G115, either in the pres-
ence or absence of the agonist mAb 20.1 or soluble pAg.
Furthermore, mAb 20.1 or pAg treatment of BTN3A1-transfected
murine cells does not support Vg9Vd2 T cell activation, which is
inconsistent with a direct Vg9Vd2 TCR-BTN3A1 interaction
mediating stimulation and instead raises the possibility that addi-
tional, primate-specific proteins are involved in this process.
Furthermore, the model proposed by Vavassori and colleagues
does not explain the specificity for BTN3A1 for Vg9Vd2 T cell
stimulation, because their proposed pAg binding pocket is
conserved between the BTN3A1 and inactive BTN3A2 isoforms.
It is also important to note that most of the physiologically
relevant pAgs are generated intracellularly. Endogenous or
‘‘self-made’’ pAgs, such as IPP or DMAPP, are products of the
intracellular mevalonate pathway and can accumulate within
the cell during metabolic changes, for example during tumori-
genesis. These metabolites also accumulate intracellularly after
addition of aminobisphosphates (NBP) that inhibit enzymes
downstream of IPP synthesis, such as farnesyl pyrophosphate
synthase. Additionally, many pathogens, such as Mycobacte-
rium tuberculosis, to which Vg9Vd2 T cells respond, are intracel-
lular pathogens, further demonstrating that rising concentrations
of intracellular pAgs are the key factor in disease surveillance.
Thus, an intracellular domain that can ‘‘sense’’ these changes
in intracellular pAg concentrations would provide a more sensi-
tive detector than an extracellular domain that would require
pAg to exit the cell and be detected by low affinity (KD z
1 mM; Vavassori et al., 2013) and at low concentrations resulting
from diffusion in the extracellular milieu.
Intracellular detection of pAgmust of course be translated into
extracellular signals that can be detected by the Vg9Vd2 TCR.
There are several ways in which this ‘‘inside-out’’ signaling
may occur. Our accumulated data suggest a model where pAg
binding to the BTN3A1 intracellular domain results in recruitment
of additional primate-specific factors and/or rearrangement of
the BTN3A1 extracellular domain that generates a stimulatory
signal directly detected by the Vg9Vd2 TCR. This is similar to
‘‘Model 2’’ proposed by Morita and colleagues (Wang et al.,
2013) based on their modeling of the B30.2 domain. Our evi-
dence that pAg binding to the B30.1 domain results in immobili-
zation of BTN3A1 molecules on the cell-surface provides an
important insight into what may be the next steps in the signaling
process for Vg9Vd2 T cell activation.498 Immunity 40, 490–500, April 17, 2014 ª2014 Elsevier Inc.B30.2 domains are present in a large number of proteins that
perform diverse functions, a subset of which are involved in
immune defense (Gober et al., 2003). These domains are gener-
ally thought to be protein-interacting modules, but their binding
partners are diverse and there is no clearly conserved binding
interface. Understanding how pAg binding to the B30.2 domain
causes BTN3A1 immobilization and leads to Vg9Vd2 TCR
engagement is an important next step. Identification of B30.2
domain binding partners, particularly those that might link these
molecules to the cytoskeleton during pAg-mediated immobiliza-
tion, would reveal the molecular steps involved in changing a
healthy, nonstimulatory cell into one that is a target for Vg9Vd2
T cell recognition. Identification of these factors will also provide
additional therapeutic targets for immunotherapy, both in cancer
and infectious disease treatments.
EXPERIMENTAL PROCEDURES
Reagents
Monoclonal antibodies were from either Beckman Coulter (fluorescein isothio-
cyanate-anti-Vd2 [#IMMU389]) or BD Biosciences (fluorescein isothiocyanate-
or phycoerythrin-cyanin 5.1-CD107a [#H4A3]). Mouse a-CD277 mAb (clone
#20.1) was kindly provided by D. Olive (INSERM U891, Marseille, France).
Synthetic bromohydrin pyrophosphate (BrHPP) was kindly provided by Innate
Pharma. Zoledronic acid monohydrate (zoledronate, NBP) andmonensin were
obtained from Sigma Aldrich. Recombinant human IL-2 (rhIL-2) was from
Chiron Therapeutics.
Cells and Functional Assays
Polyclonal human Vg9Vd2 T cells were cultured in complete RPMI 1640
medium (10% FCS, 2 mM L-glutamine, 10 mg/ml streptomycin, 100 IU/ml
penicillin) supplemented with 300 IU/ml rhIL-2. HEK sh 284 cells, which do
not express BTN3A isoforms after shRNA-mediated silencing, were gener-
ated from HEK293FT target cells as previously described (Harly et al.,
2012) and cultured in complete RPMI 1640 medium. For CD107a expression
assays, target cells were pretreated for 2 hr at 37C with either CD277-
specific mAb or NBP (zoledronate) at the indicated concentrations. Treated
cells were next extensively washed and cocultured together with Vg9Vd2
T cells at 37C in complete RPMI 1640 medium in the presence of 10 mM
monensin and fluorochrome-labeled CD107a-specific mAb. After 4 hr,
cells were harvested, stained with fluorochrome-labeled Vd2 TCR-specific
mAb, and analyzed by flow cytometry. Data were collected on FACSCantoII
and FacsCalibur cytometers (BD Biosciences) and analyzed with FlowJo
software (Tree Star). TNF-a concentration was assessed by a biological
assay based on WEHI164 clone 13 cell viability as described (Espinosa
et al., 2001).
Crystallization
Large hexagonal crystals of apo B30.2 were obtained by using sitting drops
consisting of 1 ml of 10 mg/ml protein as purified with an additional 4 mM
b-mercaptoethanol in the protein solution and 1 ml of mother liquor containing
0.2 M MgCl2, 22% PEG3350. Crystals were cryo-protected by sequentially
transferring crystals to drops containing the mother liquor with an additional
5%, then 10%, and finally 20% glycerol before freezing. cHDMAPP-soaked
crystals were generated as follows: crystals were grown via hanging drops
with buffer conditions above except without b-mercaptoethanol. Slides with
hanging drop were crosslinked by transferring the slide over a sitting drop
containing 2 ml of 25% glytaraldehyde (pH 3.0) (Sigma grade I) (Andersen
et al., 2009; Lusty, 1999). Crystals were crosslinked for between 10 min
and 3 hr without observable damage. After crosslinking, crystals were trans-
ferred into a drop containing mother liquor with an additional 100 mM
cHDMAPP. Crystals were soaked for up to 2 hr and unlike apo crystals did
not show signs of damage. Crystals were then cryo-protected as above but
with an additional 75, then 50, then 0 mM cHDMAPP in the cryo-protectant
drops.
Immunity
BTN3A1 B30.2 Domain Mediates Vg9Vd2 pAg ActivationData Collection and Processing
X-ray data sets for the B30.2 apo crystals were collected at the Advanced
Photon Source (APS) beamline 23-ID-B on a MAR300 CCD at 100
K. A com-
plete data set was collected over 150 images using a 1 oscillation at a wave-
length of 1.033 3 1010 m. HKL2000 was used to index, integrate, and scale
the data (Otwinowski and Minor, 1997). An initial molecular replacement solu-
tion was obtained with PHASER with PDB entry 2WL1 as a search model
(McCoy et al., 2007; Weinert et al., 2009). The initial model was improved by
multiple rounds of manual building via Coot followed by automated individual
site and B-factor refinement by Phenix (Adams et al., 2010).
The cHDMAPP complexed B30.2 data set was collected at APS beamline
24-ID-E on a ADSC Quantum 315 CCD at 100K. A complete data set was
collected over 150 images using a 0.5 oscillation at a wavelength of
0.97915 3 1010 m. XDS and Scala were used to index, integrate, and scale
the data. An initial molecular replacement solution was determined with the
apo B30.2 structure as a search model and Rfree flags from the apo B30.2
structure were copied to the complex data set to prevent model bias. The
structure was refined as above. Isomorphous difference maps and omit
maps were calculated with Phenix and CCP4, respectively (Winn et al.,
2011). The electrostatic surface potential of B30.2 was calculated with the
APBS electrostatic package for Pymol (Baker et al., 2001). All structural figures
were generated by Pymol (DeLano Scientific).
Molecular Docking Simulation
Autodock Vina v.1.1.2 was used to perform docking calculations on the ligand
HDMAPP to the B30.2 structure (Trott and Olson, 2010). Because of the sto-
chastic nature of Autodock Vina, we ran the docking calculation five times,
yielding the same top-scoring structure for each ligand in four of the five
runs. Vina was run with an x, y, z box size of 22, 16, 28 centered at x, y, z
coordinates 0.7, 20.4, 20.4 with all nonflexible side chains in the B30.2
structure. All other Vina parameters were set to the default.
Isothermal Titration Calorimetry
Protein samples for ITC were concentrated to 10 mg/ml and purified over a
Superdex 200 column into 20 mM HEPES (pH 7.4), 150 mM NaCl. Concentra-
tion of peak fractions was determined from A280 using the theoretical
extinction coefficient, pooled, and diluted to 100 mM. IPP and HDMAPP
were obtained from Echelon Biosciences, and cHDMAPP and EtPP were
kindly provided by Innate Pharma. ITC data were collected with 100 mM
B30.2 in the cell and 2mMpAg in the syringe on aMicroCal iTC200 (GEHealth-
care Life Sciences) at 25C using an initial injection of 0.4 ml followed by 19 2 ml
injections. A second measurement of the interaction between the BTN3A1
extracellular domain and cHDMAPP was performed at 15C. B30.2 mutant
experiments were performed with 25 mM protein in the cell with 500 mM pAg
in the syringe, as were the BTN3A1 and BTN3A3 B30.2 domain comparisons.
ITC binding fits were determined after reference subtraction of injections of the
ligand into a cell containing only buffer from the experimental results. Fits were
determined with the Microcal Origin software. Because of the weak affinity of
IPP for the B30.2 domain of BTN3A1, the stoichiometry (N) of the interaction
was set to 1 during fitting.
Additional protocols are described in detail in the Supplemental Experi-
mental Procedures, including expression of full-length and chimeric BTN3 pro-
teins into rodent cells, expression of full-length chimeric BTN3A1 proteins for
FRAP analysis, FRAP experiments and data analysis, protein expression and
purification, and surface plasmon resonance and KD estimation.
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